Cardiovascular · ACE InhibitorSafety Signalcommercialnear-term

Crescent Pharma recalls Ramipril 2.5 mg Capsules due to packaging error

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Crescent Pharma Limited5 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/13/2026, 6:33:44 PM

Assessment confidence: 58% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The recall of Ramipril 2.5 mg Capsules due to a packaging error poses significant risks to Crescent Pharma's market reputation and sales within the cardiovascular segment. Portfolio teams must closely monitor the situation and prepare strategies to address potential reputational damage. Regulatory context from MHRA (Guidance: Best practice in the labelling and packaging of medicines) supports the near-term read. Assessment grounded in 19 ranked evidence items (5 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of this recall on sales and consider strategies to mitigate reputational damage. The strongest clinical anchor is Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With CDK4/6 Inhibitor and an Aromata (ClinicalTrials.gov), sponsor/company relevance (novartis). In Cardiovascular · ACE Inhibitor, 5 regulatory and 2 competitive items passed relevance filtering for Crescent Pharma Limited.

Competitive Pressure

The most relevant competitive pressure comes from Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders (Lilly) — sponsor/company relevance (lilly). Secondary pressure from Allurion Gastric Balloon Safety Update: Risks of Obstruction and Perforation. This recall may impact Crescent Pharma's reputation and market share in the cardiovascular segment, particularly among ACE inhibitors.

Regulatory Outlook

Regulatory risk is concentrated around Guidance: Best practice in the labelling and packaging of medicines (MHRA). Regulatory pathway relevance (label). Relevant agencies in corpus: MHRA, FDA. The recall may prompt regulatory scrutiny and necessitate compliance actions, impacting future approvals and labeling for Crescent Pharma's products.

Key Risks

Elevated medium regulatory exposure for Crescent Pharma Limited could delay market entry or constrain labeling if agency review intensifies.
Signal severity is high — leadership review is warranted.

Key Opportunities

This recall could lead to a temporary decline in sales and market share for Crescent Pharma, particularly in the competitive ACE inhibitor market.
This guidance explains the legal framework for labelling and packaging as described in UK legislation and gives best practice for producing medicines labelling and packaging.
How to package medicines for sale and what information you must provide to consumers and healthcare professionals.
CDK4/6 inhibitors (CDK4/6i) represent the standard treatment for HR+/HER2- ABC. The study assessed the efficacy and safety profiles of CDK4/6i from first-line (1 L) to third-line (3 L) in patients with HR+/HER2- ABC from high-altitude versus low-altitude regions.
Upside for Crescent Pharma Limited may improve if Nephrotoxic medication burden and drug-related problems in patients with chronic kidney disease using SGLT2 inhibitors. (PubMed) delivers favorable follow-through.

What Would Change This Assessment

This becomes more urgent if Monitor for updates on the recall process and any regulatory actions that may follow.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond near term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Guidance: Best practice in the labelling and packaging of medicines
MHRAhigh relevance
Regulatory pathway relevance (label)
FDA document
View source
Medicines: packaging, labelling and patient information leaflets
MHRAhigh relevance
Regulatory pathway relevance (label)
FDA document
View source
Class 3 Medicines Recall: Flamingo Pharma UK Ltd, Flucloxacillin Capsules BP 500mg, EL(26)A/32
MHRAhigh relevance
Moderate corpus alignment
FDA document
View source
Class 4 Medicines Defect Notification: Brancaster Pharma Limited, Benzylpenicillin benzathine 1.2 Million I.U. and 2.4 Million I.U. powder for suspension for injection, EL(26)A/30
MHRAmedium relevance
Moderate corpus alignment
FDA document
View source
Report on the State of Pharmaceutical Quality
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With CDK4/6 Inhibitor and an Aromata
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Novartis)
FDA document
View source
A Phase I Clinical Trial to Evaluate the Pharmacokinetic and Safety of Ammoxetine Hydrochloride Enteric-Coated Tablets in Participants With Mild Hepatic Impairment, Moderate Hepatic Impairment, and No
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Safety, Tolerability and Levodopa Pharmacokinetics Study of Repeated ND0612 in Parkinson's Disease Patients
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Phase Ib, Randomized, Double-blind, Placebo-Controlled, Dose-Escalation Study of Alpha-0261 Tablets to Assess Safety and Tolerability in Patients With Chronic Spontaneous Urcaria (Part 1) and Food Eff
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Safety, PK/PD (Pharmacokinetics/Pharmacodynamics) and Efficacy of ACP-001 Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders
Lillyhigh relevance
Sponsor/company relevance (Lilly)
FDA document
View source
Allurion Gastric Balloon Safety Update: Risks of Obstruction and Perforation
Humanexa Signalsmedium relevance
Moderate corpus alignment

Safety, tolerability, and pharmacokinetics/-dynamics of the dipeptidyl peptidase 3-inhibiting antibody Procizumab in a first-in-human trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Safety and efficacy of ashwagen (a standardized withania somnifera extract) in stress and anxiety with hypertension and associated cardiometabolic risk factors: a randomized, placebo-controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Insect-based models in pharmaceutical ecotoxicology: a bibliometric and narrative review.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Mapping the global landscape of research on immune checkpoint inhibitor-associated cardiotoxicity: A quantitative and visualized bibliometric study (2016-2025).
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Efficacy and safety profiles of CDK4/6 inhibitor in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) from the high
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Nephrotoxic medication burden and drug-related problems in patients with chronic kidney disease using SGLT2 inhibitors.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Comparative efficacy, recovery, and pigmentary safety of radiofrequency microneedling and fractional carbon dioxide laser for facial atrophic acne scars: a prospective randomized split-face trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Crescent Pharma Limited

Commercial impact

medium

This recall could lead to a temporary decline in sales and market share for Crescent Pharma, particularly in the competitive ACE inhibitor market.

Regulatory impact

medium

The recall may prompt regulatory scrutiny and necessitate compliance actions, impacting future approvals and labeling for Crescent Pharma's products.

What to watch

Monitor for updates on the recall process and any regulatory actions that may follow.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.